MA30153B1 - Anticorps anti-ox40l et methodes correspondantes - Google Patents

Anticorps anti-ox40l et methodes correspondantes

Info

Publication number
MA30153B1
MA30153B1 MA31104A MA31104A MA30153B1 MA 30153 B1 MA30153 B1 MA 30153B1 MA 31104 A MA31104 A MA 31104A MA 31104 A MA31104 A MA 31104A MA 30153 B1 MA30153 B1 MA 30153B1
Authority
MA
Morocco
Prior art keywords
corresponding methods
ox40l antibodies
ox40l
antibodies
methods
Prior art date
Application number
MA31104A
Other languages
English (en)
French (fr)
Inventor
Flavius Martin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA30153B1 publication Critical patent/MA30153B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA31104A 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes MA30153B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
MA30153B1 true MA30153B1 (fr) 2009-01-02

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31104A MA30153B1 (fr) 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes

Country Status (18)

Country Link
US (2) US7812133B2 (cg-RX-API-DMAC7.html)
EP (1) EP1973949A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009519718A (cg-RX-API-DMAC7.html)
KR (1) KR20080080639A (cg-RX-API-DMAC7.html)
CN (1) CN101374865A (cg-RX-API-DMAC7.html)
AR (1) AR057253A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006343459A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0621065A2 (cg-RX-API-DMAC7.html)
CA (1) CA2633602A1 (cg-RX-API-DMAC7.html)
CR (1) CR10069A (cg-RX-API-DMAC7.html)
EC (1) ECSP088543A (cg-RX-API-DMAC7.html)
IL (1) IL191820A0 (cg-RX-API-DMAC7.html)
MA (1) MA30153B1 (cg-RX-API-DMAC7.html)
NO (1) NO20083147L (cg-RX-API-DMAC7.html)
RU (1) RU2426744C2 (cg-RX-API-DMAC7.html)
TW (1) TW200732349A (cg-RX-API-DMAC7.html)
WO (1) WO2007133290A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200804868B (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
JP5371142B2 (ja) 2006-07-14 2013-12-18 エフ・イ−・アイ・カンパニー マルチソース型のプラズマ集束イオン・ビーム・システム
MX2009009194A (es) * 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
PH12013500354B1 (en) 2010-08-23 2018-10-19 Univ Texas Anti-ox40 antibodies and methods of using the same
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ME03071B (me) 2011-04-21 2019-01-20 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
JP6038920B2 (ja) * 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
JP6886816B2 (ja) 2013-09-09 2021-06-16 カニムガイド セラピューティックス アーベー 免疫系調節薬
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
LT3265123T (lt) * 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
BR112020010137A2 (pt) 2017-11-24 2020-10-13 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-ox40 e usos dos mesmos
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
JP7688150B2 (ja) * 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
AU2022326849A1 (en) * 2021-08-10 2024-03-21 Kymab Limited Treatment of atopic dermatitis
CA3258958A1 (en) * 2022-02-09 2023-08-17 Petmedix Ltd THERAPEUTIC ANTIBODIES
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025158009A1 (en) * 2024-01-26 2025-07-31 Almirall S.A. Bispecific molecules and methods of treatment using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
US20030012781A1 (en) * 2000-06-06 2003-01-16 Anderson Darrell Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
AU2002365814A1 (en) 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2560889A1 (en) 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
JP2006081061A (ja) 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声／映像出力装置
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
MX2009009194A (es) 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.

Also Published As

Publication number Publication date
NO20083147L (no) 2008-09-16
ZA200804868B (en) 2009-10-28
AR057253A1 (es) 2007-11-21
JP2009519718A (ja) 2009-05-21
IL191820A0 (en) 2008-12-29
WO2007133290A2 (en) 2007-11-22
RU2426744C2 (ru) 2011-08-20
CN101374865A (zh) 2009-02-25
WO2007133290A3 (en) 2008-01-10
EP1973949A2 (en) 2008-10-01
CA2633602A1 (en) 2007-11-22
BRPI0621065A2 (pt) 2011-11-29
TW200732349A (en) 2007-09-01
US20090053230A1 (en) 2009-02-26
US7812133B2 (en) 2010-10-12
WO2007133290A8 (en) 2008-03-27
KR20080080639A (ko) 2008-09-04
ECSP088543A (es) 2008-07-30
RU2008129111A (ru) 2010-01-27
US20100272738A1 (en) 2010-10-28
CR10069A (es) 2008-10-10
AU2006343459A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EP1896073A4 (en) ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
EA200702643A1 (ru) Антитела, связывающие tweak
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
TW200626171A (en) Fixed dosing of HER antibodies
EA200701918A1 (ru) Белок липокалин
TW200709817A (en) Platform antibody compositions
DK1804589T3 (da) Fedtsammensætninger
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
EA200702193A1 (ru) Гликозилирование белков
ATE499341T1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2- ennitril als geruchs- und geschmacksstoff
FR2894983B1 (fr) Test de caracterisation des anticorps.
WO2007073567A3 (en) Compositions and methods of modulating the immune response
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13